TL
TLX.AU TELIX Pharmaceuticals Ltd
- Market cap
- AUD 4.46B
- P/E
- 87.5x
- P/B
- 6.45x
- ROE
- 30.8%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is TLX.AU undervalued?
Graham numberThe Graham number of TELIX Pharmaceuticals Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TELIX Pharmaceuticals Ltd fundamental analysis
5 of 22 checks passedROE 2/2
High return on equity (30.8%), above 20%.
ROA 1/1
Return on assets (11.0%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-114.8%) is below the industry median (-5.3%).
Revenue Growth 2/2
Revenue grew 72.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
High debt to equity (118.9%), above 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is negative, against interest expense, below 5x.
PE vs Market 0/1
PE (87.5x) is above the market median (15.0x).
PE vs Industry 0/1
PE (87.5x) is above the industry median (16.3x).
PBV 0/1
Price to book (6.5x) is above the industry median (4.4x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 564.9, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
TELIX Pharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TELIX Pharmaceuticals Ltd
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The co…
Full company profileTELIX Pharmaceuticals Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TELIX Pharmaceuticals Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 403K | 195K | 3.49M | 5.21M | 7.60M | 160M | 503M | 783M | 817M | 1.87B |
| Gross Profit | 0.00 | -3.79K | 195K | -11.9M | 3.19M | -29.8M | 29.3M | 314M | 510M | 434M | 965M |
| Operating Income | -30.0K | -6.52M | -27.6M | -40.3M | -49.3M | -81.2M | -73.2M | 52.6M | 82.1M | 18.1M | -53.9M |
| EBITDA | -14.0K | -5.70M | -27.6M | -24.5M | -54.2M | -70.1M | -92.8M | 23.1M | 90.1M | 40.2M | 46.8M |
| Net Income | -44.0K | -6.38M | -13.8M | -27.9M | -44.9M | -80.5M | -104M | 5.21M | 49.9M | -7.24M | 150M |
| EPS | 0.00 | -0.05 | -0.07 | -0.12 | -0.17 | -0.29 | -0.34 | 0.02 | 0.14 | -0.02 | 0.42 |
| Balance Sheet | |||||||||||
| Total Assets | - | 51.1M | 76.7M | 103M | 158M | 110M | 255M | 406M | 1.52B | 1.18B | 1.36B |
| Total Liabilities | - | 1.80M | 23.8M | 32.5M | 78.8M | 106M | 175M | 256M | 948M | 767M | 874M |
| Shareholders' Equity | - | 49.3M | 52.9M | 70.1M | 79.0M | 2.16M | 80.0M | 149M | 568M | 416M | 487M |
| Cash & Short-term Investments | - | 48.8M | 25.8M | 44.6M | 77.9M | 22.0M | 116M | 123M | 710M | 142M | 252M |
| Total Debt | - | 345K | 1.73M | 2.13M | 2.21M | 2.54M | 10.4M | 17.4M | 581M | 467M | 580M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.03M | -6.03M | -20.7M | -23.3M | 1.96M | -59.3M | -64.0M | 23.9M | 43.0M | -17.6M | 90.3M |
| Capital Expenditure | 5.64K | 5.64K | 403K | 468K | 322K | 1.34M | 13.9M | 10.8M | 34.0M | 38.5M | 74.3M |
| Free Cash Flow | - | -6.04M | -20.7M | -23.8M | 1.64M | -60.7M | -77.8M | 13.1M | 9.00M | -56.1M | 16.0M |
| Ratios | |||||||||||
| ROE | - | -12.9% | -26.1% | -39.8% | -56.8% | -3,730.8% | -130.1% | 3.5% | 8.8% | -1.7% | 30.8% |
| ROA | - | -12.5% | -18.0% | -27.2% | -28.4% | -73.3% | -40.8% | 1.3% | 3.3% | -0.6% | 11.0% |
| Net Profit Margin | - | -1,580.6% | -7,087.1% | -799.6% | -861.1% | -1,059.9% | -65.0% | 1.0% | 6.4% | -0.9% | 8.0% |
| Debt to Equity | - | 0.01x | 0.03x | 0.03x | 0.03x | 1.18x | 0.13x | 0.12x | 1.02x | 1.12x | 1.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TELIX Pharmaceuticals Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | AUD 168M | 0.54 | - |
| 2021 | - | - | - |
| 2020 | AUD 34.5M | 0.13 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | AUD 54.8M | 0.43 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns TELIX Pharmaceuticals Ltd
- Insiders 15.82%
- Institutions 34.11%
- Public & others 50.07%
- Shares outstanding 340M
- Free float 274M
Top funds holding TLX.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SPDR Portfolio Developed World ex-US ETF | 102K | 0.04% | - | Feb 2021 |
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 97.2K | 0.03% | - | Feb 2021 |
TELIX Pharmaceuticals Ltd company profile
- Company name
- TELIX Pharmaceuticals Ltd
- Ticker
- TLX.AU
- ISIN
- AU000000TLX2
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,120
- Fiscal year end
- December
- Address
- 55 Flemington Road, North Melbourne, VIC, Australia, 3051
- Phone
- 61 3 9093 3855
- Website
- telixpharma.com
About TELIX Pharmaceuticals Ltd
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TELIX Pharmaceuticals Ltd management
10- Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.DCo-Founder, MD, Group CEO & Executive Director · born 1975
- Mr. Darren Smith B.Bus., FCPA, M.B.A.Group Chief Financial Officer · born 1965
- Mr. Darren Patti Pharm.D.Group Chief Operating Officer · born 1972
- Dr. David N. Cade M.B.A., M.D., MBBSGroup Chief Medical Officer · born 1969
- Dr. Paul SchafferSVP of Research & Development
- Mr. Craig UlrickChief Information Officer
- Ms. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor Relations
- Mr. Christian Krautkramer J.D.Group General Counsel
- Mr. Thomas FrommSenior VP of Sales
- Ms. Meredith Crowe BDESSenior Vice President of Global People & Culture